Erratum: Investing in non-communicable diseases: an estimation of the return on investment for prevention and treatment services (The Lancet (2018) 391(10134) (2071–2078) (S0140673618306652) (10.1016/S0140-6736(18)30665-2));Investing in non-communicable diseases: an estimation of the return on investment for prevention and treatment services

The Lancet

Volumn 391, Issue 10134, 2018, Pages 2071-2078

  Bertram, Melanie Y ^a   Sweeny, Kim ^b   Lauer, Jeremy A ^a   Chisholm, Daniel ^a   Sheehan, Peter ^b   Rasmussen, Bruce ^b   Upreti, Senendra Raj ^c   Dixit, Lonim Prasai ^a   George, Kenneth ^d   Deane, Samuel ^d  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b VICTORIA UNIVERSITY   (Australia)

^c Minister for Health and Population Nepal   (Nepal)

^d Ministry of Health Barbados   (Barbados)

Author keywords

[No Author keywords available]

Indexed keywords

BARBADOS; CARDIOVASCULAR DISEASE; COST BENEFIT ANALYSIS; DISEASE CONTROL; HEALTH CARE COST; HUMAN; INVESTMENT; NEPAL; NON COMMUNICABLE DISEASE; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SMOKING REGULATION; SODIUM RESTRICTION; TOBACCO; ECONOMIC MODEL; HEALTH CARE DELIVERY; INTERNATIONAL COOPERATION; PREMATURE MORTALITY; PROCEDURES;

CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; DELIVERY OF HEALTH CARE; HUMANS; INTERNATIONAL COOPERATION; MODELS, ECONOMIC; MORTALITY, PREMATURE; NONCOMMUNICABLE DISEASES;

EID: 85044865507     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(18)30848-1     Document Type: Erratum

References (26)

1. WHO. Non-communicable disease fact sheet. http://www.who.int/mediacentre/factsheets/fs355/en/, January, 2015 (accessed June 17, 2016).
2. GBD 2016 DALY and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390 (2018), 1260–1344.
3. Abegunde, DO, Mathers, CD, Adam, T, Ortegon, M, Strong, K, The burden and costs of chronic diseases in low-income and middle-income countries. Lancet 370 (2007), 1929–1938.
4. Chaker, L, Falla, A, van der Lee, SJ, et al. The global impact of non-communicable diseases on macro-economic productivity: a systematic review. Eur J Epidemiol 30 (2015), 357–395.
5. WHO. Global action plan for the prevention and control of noncommunicable diseases 2013–2020. 2013, World Health Organization, Geneva.
6. Chisholm, D, Abagunde, D, Mendis, S, Scaling up action against noncommunicable diseases: how much will it cost?. 2011, World Health Organization, Geneva.
7. WHO. Governance: updating Appendix 3 of the WHO Global NCD Action Plan 2013–2020. http://who.int/ncds/governance/appendix3-update/en/, April 12, 2017 (accessed July 18, 2017).
8. Jamison, DT, Summers, LH, Alleyne, G, et al. Global health 2035: a world converging within a generation. Lancet 382 (2013), 1898–1955.
9. Stenberg, K, Axelson, H, Sheehan, P, et al. Advancing social and economic development by investing in women's and children's health: a new Global Investment Framework. Lancet 383 (2014), 1333–1354.
10. Stiglitz, JE, Sen, A, Fitoussi, J-P, The measurement of economic performance and social progress revisited. 2009, Centre de Recherche en Economie de Sciences, Paris.
11. Schmidt-Traub, G, Sachs, JD, Financing sustainable development: implementing the SDGs through effective investment strategies and partnerships. 2015, Sustainable Development Solutions Network, Paris.
12. Lauer, JA, Röhrich, K, Wirth, H, Charette, C, Gribble, S, Murray, CJ, PopMod: a longitudinal population model with two interacting disease states. Cost Eff Resour Alloc, 1, 2003, 6.
13. Johns, B, Baltussen, R, Hutubessy, R, Programme costs in the economic evaluation of health interventions. Cost Eff Resour Alloc, 1, 2003, 1.
14. Viscusi, WK, Aldy, J, The value of a statistical life: a critical review of market estimates throughout the world. J Risk Uncertainty 27 (2003), 5–76.
15. WHO. MPOWER: a policy package to reverse the tobacco epidemic. 2008, World Health Organization, Geneva.
16. WHO. SHAKE the salt habit. 2017, World Health Organization, Geneva.
17. WHO. Package of essential non-communicable disease interventions for primary health care in low resource settings. 2010, World Health Organization, Geneva.
18. Roth, GA, Huffman, MD, Moran, AE, et al. Global and regional patterns in cardiovascular mortality from 1990 to 2013. Circulation 132 (2015), 1667–1678.
19. Bloom, DE, Cafiero, ET, Jané-Llopis, E, The global economic burden of non-communicable diseases. 2011, World Economic Forum, Geneeva.
20. Ortegón, M, Lim, S, Chisholm, D, Mendis, S, Cost effectiveness of strategies to combat cardiovascular disease, diabetes, and tobacco use in sub-Saharan Africa and South East Asia: mathematical modelling study. BMJ, 344, 2012, e607.
21. Atun, R, Jaffar, S, Nishtar, S, et al. Improving responsiveness of health systems to non-communicable diseases. Lancet 381 (2013), 690–697.
22. Samb, B, Desai, N, Nishtar, S, et al. Prevention and management of chronic disease: a litmus test for health-systems strengthening in low-income and middle-income countries. Lancet 376 (2010), 1785–1797.
23. Duran, A, Khot, A, Strengthening the health system to better confront noncommunicable diseases in India. Indian J Community Med 36:suppl 1 (2011), S32–S37.
24. Robinson, HM, Hort, K, Non-communicable diseases and health systems reform in low-and-middle-income countries. Pac Health Dialog 18 (2012), 179–190.
25. Chisholm, D, Sweeny, K, Sheehan, P, et al. Scaling-up treatment of depression and anxiety: a global return on investment analysis. Lancet Psychiatry 3 (2016), 415–424.
26. Sheehan, P, Sweeny, K, Rasmussen, B, et al. Building the foundations for sustainable development: a case for global investment in the capabilities of adolescents. Lancet 390 (2017), 1792–1806.